UK trial into coronavirus drug could bolster defences of at risk patients | ||
Monday, 4 May 2020 ()
'In an ideal world we would see a significant improvement in the health of the patients receiving the drug, a reduction in those requiring intensive care and ventilation', research leader says |
| 0 shares | |
Credit: ANI - Published
Trial of 'Mycobacterium w' drug completed: Director, PGIMER Chandigarh 01:13Post Graduate Institute of Medical Education and Research (PGIMER) Director Dr Jagat Ram informed that the trial of Mycobacterium w (Mw) drug has been completed. "The safety trial of 'Mw vaccine' drug has been completed. But its actual trial will be conducted on 40 patients at PGI Chandigarh,... |